Merge Healthcare Inc. (MRGE) recently entered into a new agreement with Cato Research Ltd. Per the agreement, Cato will provide the proprietary etrials EDC solution through Merge’s technology transfer program. Financial terms of the agreement have not been disclosed.
The new agreement will bring in additional technologies for clinical trials management. It also extends the relationship Merge already has with Cato for five years.
Cato can now leverage Merge’s technology transfer model to provide cost-effective clinical studies for its customers. The etrials EDC solution is built on the SaaS platform, which enables customers to license it on a subscription or study basis. Furthermore, Merge’s etrials ePRO and IVR solutions can be incorporated with the EDC system to provide comprehensive eClinical solutions to customers.
Merge is a healthcare software and services company focused on integrating radiology workflow to improve productivity, profitability and patient care by fusing business and clinical workflow, and intelligently managing and distributing diagnostic images and information throughout the healthcare enterprise.
Merge was paralyzed by several issues in the past like a dwindling cash balance, management turnover, accounting miscues and litigations. The real turnaround started from the second quarter of 2008 when the company received a much-needed cash infusion of $20 million from Merrick RIS, LLC in May 2008.
Read the full analyst report on “MRGE”
Zacks Investment Research
